You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

80 Results
Guidelines and Advice
Status: Current
Version: 2
Jan 2022
Guidelines and Advice
Status: Current
ID: 2-6
Version: 2
Sep 2022
Guidelines and Advice
Status: Current
ID: 11-6
Version: 2
Feb 2022
Guidelines and Advice
Status: Current
ID: 4-13
Version: 3
Mar 2022
Guidelines and Advice
Status: Current
ID: 7-16
Version: 4
Dec 2022
Guidelines and Advice
Status: Current
Sep 2022
Guidelines and Advice
Status: Current
Version: 2
Mar 2022
Guidelines and Advice
Status: Current
Version: 2
Mar 2022
Guidelines and Advice
Status: Current
Version: 1
Feb 2022
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
CISplatin,
gemcitabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2022
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant, Adjuvant, Palliative
Drugs Used:
methotrexate,
vinBLAStine,
DOXOrubicin,
CISplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2022
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - In Combination with Platinum and Pemetrexed for First Line Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab,
pemetrexed,
CISplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2022

Pages